In colorectal cancer cells, Silmitasertib inhibits the binding of CK2 to its target, Akt, thereby inhibiting the PI3K/Akt/mTORC1 signaling pathway, and tumor growth (159). This evidence concerns the gene AKT1 and neoplasm.